Talphera (TLPH) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Jun, 2026Opening remarks and agenda
Chairman welcomed attendees, introduced board members, executive officers, and the independent auditor present for the meeting.
Outlined the meeting agenda, including formal business and a Q&A session following the official proceedings.
Board and executive committee updates
Three Class III director nominees—Marina Bozilenko, Joseph Todisco, and Mark Wan—were presented for election to serve until the 2029 annual meeting.
Shareholder proposals
Five proposals were presented: election of directors, ratification of the independent auditor, advisory vote on executive compensation, amendment to the 2020 Equity Incentive Plan, and amendment to the 2011 Employee Stock Purchase Plan.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Talphera
- Q2 net loss was $4.3M as nafamostat gains guideline support and CRRT market expands 21%.TLPH
Q2 2026 - NEPHRO CRRT study enrollment surpassed 50%, Q1 net loss was $2.6M, cash at $21.1M.TLPH
Q1 2026 - Board recommends approval of all proposals, including director elections and plan amendments.TLPH
Proxy filing - Annual meeting seeks approval for directors, auditor, compensation, and equity plans.TLPH
Proxy filing - Niyad targets a major gap in anticoagulation for dialysis, with pivotal study completion expected in 2026.TLPH
Corporate presentation - Resale registration for $4.1M in shares and warrants; acute care focus; no proceeds to issuer.TLPH
Registration filing - Nephro CRRT study hits 50% enrollment; $20.4M cash at year-end 2025; Niyad seen as promising.TLPH
Q4 2025 & Investor Day - Pivotal phase III trial of Niyad targets 2025 finish, with strong IP and market prospects.TLPH
Maxim Group’s 2024 Healthcare Virtual Summit - Q2 net loss narrowed to $3.8M, cash rose to $14M, and NEPHRO study enrollment accelerated.TLPH
Q2 2024